12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CF101: Completed Phase III enrollment

OphthaliX completed enrollment of 236 patients in a double-blind, placebo-controlled, international Phase III trial evaluating 0.1 and 1 mg oral CF101 twice daily for 24 weeks. OphthaliX, formerly Denali Concrete Management...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >